Foamix' emollient foam platform awarded Mexican patent

Foamix Ltd., a leading developer of topical foams for dermatological and gynecological use, announced today that it has been awarded Mexican Patent Registration No. 268451 entitled "Cosmetic and Pharmaceutical Foam." The patent covers Foamix's vehicles, compositions and cosmetic and pharmaceutical uses thereof based on the company's Emollient Foam technology platform. Claimed uses include the treatment of bacterial, fungal and viral infections, inflammatory conditions, and many other dermatological and mucosal disorders, including vaginal disorders.

"The continuing demand for our platform foam technology and our products is international. By incorporating drugs in foam vehicles, we can achieve advanced foam products with properties that afford higher patient compliance, improved convenience, and better efficacy. Additionally, formulating active ingredients in Foamix foam vehicles facilitates effective product life-cycle management, backed by Foamix's extensive patent portfolio," said Dr. Dov Tamarkin, the Company's CEO.

"We actively file for patent protection for our platform technologies and range of products in development. A key component of our business strategy is to create and build on a strong patent portfolio to offer protection to a growing range of foam technologies and products, which we can license out to our clients. Having an Emollient-Foam patent approved in Mexico is one more degree of protection that we can provide to our licensees and add to our granted "Cosmetic and Pharmaceutical Foam" patents in New Zealand and South Africa," explained David Schuz, Foamix's Senior Vice President of Intellectual Property and Head of Strategic Research.

Foamix expends significant resources on protecting its intellectual property. To date, Foamix has seventeen issued patents worldwide covering its foam and OilGel technology platforms and in excess of 150 pending applications of which more than a third are filed in the United States. The Company employs a leading U.S. patent counsel (WilmerHale LLC).

Source:

Foamix Ltd

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Utilizing process Raman in optimizing cultivated meat production